SCHEMBL639436

SCHEMBL639436

COC(=O)c1ccc(-c2c[nH]c(=S)[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
GFER P55789 2/20 0.50
GAA P10253 1/20 0.50
ALDH1A1 P00352 5/20 0.49
MAPT P10636 4/20 0.49
POLB P06746 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
MCL1 Q07820 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HDAC8 Q9BY41 1/20 0.47
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA12 O43570 3/20 0.44
CA9 Q16790 3/20 0.44
CA14 Q9ULX7 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3343847 0.75 ALDH1A1 (0.58) KDM4EGFERGAAALDH1A1MAPT
SCHEMBL2244842 0.74 ALDH1A1 (0.36) KDM4EGFERGAAALDH1A1POLB
Biphenyl Dimethyl Dicarboxylate SCHEMBL68521 0.73 CA1 (0.70) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL19387238 0.73 CA1 (0.70) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL24727844 0.72 HDAC1 (0.63) KDM4EALDH1A1MAPTL3MBTL1CA1
SCHEMBL3344780 0.72 GAA (0.64) KDM4EGFERGAAALDH1A1MAPT
Biphenyl Dimethyl Dicarboxylate SCHEMBL2890577 0.71 CA1 (0.67) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL20640913 0.71 CYP1A2 (0.43) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL23600 0.71 CA1 (0.80) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL28993944 0.71 CA1 (0.80) KDM4EALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US claimed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US claimed
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US disclosed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF TYR, TH, PAH KDM4E 582/4885GFER 2966/4885GAA 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.